- Home
- STI vs OPTN Comparison
STI vs OPTN Comparison
Compare STI & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STI
- OPTN
- Stock Information
- Founded
- STI 2014
- OPTN 2010
- Country
- STI United States
- OPTN United States
- Employees
- STI N/A
- OPTN N/A
- Industry
- STI
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- STI
- OPTN Health Care
- Exchange
- STI NYSE
- OPTN Nasdaq
- Market Cap
- STI 51.2M
- OPTN 55.4M
- IPO Year
- STI N/A
- OPTN 2017
- Fundamental
- Price
- STI $0.39
- OPTN $5.77
- Analyst Decision
- STI
- OPTN Strong Buy
- Analyst Count
- STI 0
- OPTN 3
- Target Price
- STI N/A
- OPTN $16.67
- AVG Volume (30 Days)
- STI 2.1M
- OPTN 18.7K
- Earning Date
- STI 03-04-2025
- OPTN 03-06-2025
- Dividend Yield
- STI N/A
- OPTN N/A
- EPS Growth
- STI N/A
- OPTN N/A
- EPS
- STI N/A
- OPTN N/A
- Revenue
- STI $5,329.00
- OPTN $75,672,000.00
- Revenue This Year
- STI N/A
- OPTN $13.42
- Revenue Next Year
- STI N/A
- OPTN $38.54
- P/E Ratio
- STI N/A
- OPTN N/A
- Revenue Growth
- STI 32.73
- OPTN 5.13
- 52 Week Low
- STI $0.27
- OPTN $4.82
- 52 Week High
- STI $4.44
- OPTN $31.50
- Technical
- Relative Strength Index (RSI)
- STI 42.70
- OPTN 44.78
- Support Level
- STI $0.39
- OPTN $5.20
- Resistance Level
- STI $0.43
- OPTN $6.49
- Average True Range (ATR)
- STI 0.03
- OPTN 0.50
- MACD
- STI 0.00
- OPTN 0.04
- Stochastic Oscillator
- STI 23.15
- OPTN 44.19
About STI SOLIDION TECHNOLOGY INC
Solidion Technology Inc is engaged in researching, developing and manufacturing battery materials and components, as well as the development and production of next-generation batteries for energy storage systems and electric vehicles for ground, air, and sea transportation. It is recognized as a global IP leader in both the high-capacity anode and the high-energy solid-state battery.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.